Install
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
- 283,142articles · 365d
- 1+ hour agolatest article
- Sep 13, 2025earliest in window
- 9%with images · 12,383 videos
- 293avg words
- business 172,975
- stocks 118,612
- markets 111,402
- investing 92,532
- stock market 91,206
- business news 75,989
- stock 71,333
- investment 70,394
- stock market news 67,205
- finance 56,899
- technology 54,612
- investment advice 53,957
- companies 49,945
- online trading 49,185
- online investment 43,606
- artificial intelligence 39,104
- online stock trading 37,095
- financial 31,434
- ai 29,687
- inc 20,547
- Economy, Business & Finance 248,814
- Finance & Business 235,635
- News 129,765
- Finance 70,486
- Business & Industrial 29,085
- Health & Wellness 11,551
- Science & Technology 9,383
- Medical 8,069
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
10+ mon, 6+ day ago (1010+ words) In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, or reported sexual side effects1,2 In a six-month open-label extension safety study, safety profile was consistent with pivotal studies and 80% of MDD patients taking CAPLYTA® achieved response, with 65% of…...
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
11+ mon, 3+ day ago (1461+ words) 17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 data evaluates the impact on sexual function in MDD, reinforcing potential to…...